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Abstract
Introduction: Acute myeloid leukaemia (AML) is an aggressive haematological malignancy which is more common in the 
elderly and has a poor 5-year survival. There are no established beneficial interventions to treat AML in elderly patients. It is 
unclear whether outpatient delivery of palliative chemotherapies could reduce the burden of disease and hospitalisation for this 
group.
Aims: To compare overall survival, response to treatment and supportive care needs between inpatient and outpatient-based 
treatments for AML in elderly patients.
Materials & Methods: We undertook a retrospective cohort study in the Haematology Department at Belfast City Hospital 
comparing overall survival (OS), treatment responses and supportive care needs between inpatient and outpatient treatments for 
AML in elderly patients. Consecutive entrants to outpatient and inpatient based clinical trials between February 2013 and January 
2017 were included. Case notes, chemotherapy charts, clinic letters, blood bank and electronic care records were analysed.
Results: OS and rates of CR (complete remission), CRi (CR with incomplete count recovery) and PR (partial response) was 
not significantly different between inpatient and outpatient regimens with a median OS of 201 vs. 124 days, respectively. No 
response was observed in 35% of patients in the inpatient group compared with 65% of the outpatient group, however this did not 
reach significance. Of patients who achieved CR/CRi in the outpatient group, 75% relapsed at a median of 271 days, compared 
with 60% of the inpatient group at a median of 209 days. At least one grade 3-4 toxicity was experienced by 90% and 83.3% 
of inpatient and outpatient groups, respectively. There was no difference in six common grade 3-4 toxicities. Patients on the 
outpatient regimen spent fewer days in hospital but had a median packed red cell use of more than twice that of the inpatient 
group. No difference was noted in infections, days on antibiotics or platelet use.
Discussion: Our data suggests that outpatient chemotherapy is safe and can reduce hospitalisation for elderly patients with 
AML, without a decline in OS or response rates. These results provide an important rationale to test the comparative efficacy 
of outpatient chemotherapy. Chemotherapy related toxicities remain a significant source of morbidity in this population and 
highlight the need to develop novel, targeted therapies for this age group.
INTRODUCTION
Acute Myeloid Leukaemia  (AML) is an aggressive group of 
haematological malignancies that are more common in the 
older population with a median age of onset at ~65years 1. 
Despite recent therapeutic advances in younger patients, little 
improvement has occurred in the survival of older patients. 
Five year survival rates remain poor at ~5% in patients >60 
years compared with up to 50% in younger patients 2,3. It 
has been established that treatment of elderly patients with 
intensive chemotherapy is often futile, resulting in more early 
deaths and unacceptable toxicities compared with younger 
age group 4. In addition, responses to chemotherapy are poorer 
and relapse rates are higher in older patients 5.
There are currently no established beneficial therapeutic 
interventions to treat AML in elderly patients  and as such, 
enrolment in clinical trials investigating combinations of 
low dose chemotherapy is the recommended approach 3,6. 
While determining the optimal chemotherapy regimens in 
the elderly has received much research interest, little attention 
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has been paid to the clinical setting needed to support their 
delivery.  It is unclear whether an outpatient delivery of such 
palliative regimens represents a treatment option which would 
potentially reduce the burden of hospitalisation and improve 
quality of life. To determine if chemotherapy regimens 
differ in efficacy or tolerability according to the clinical 
setting they are delivered in, we undertook a retrospective 
analysis of an outpatient based chemotherapy regimen (Phase 
II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in 
combination with Vorinostat in patients with Acute Myeloid 
Leukaemia or High Risk Myelodysplastic Syndromes 
Ineligible for Intensive Chemotherapy- RAvVA trial) 7 and an 
inpatient based low dose chemotherapy regimen in patients 
with high risk MDS and AML unsuitable for intensive 
chemotherapy.  
AIM & STUDY DESIGN
This was a retrospective cohort study carried out in the 
Haematology Department of Belfast City Hospital to compare 
overall survival, response to treatment and supportive care 
needs between inpatient and outpatient-based protocols for 
AML in elderly patients. Inpatient based treatment consisted 
of 4 cycles of low dose cytarabine (20mg BD subcutaneously, 
days 1-10) +/- another experimental drug at 28-42-day 
intervals as part of the AML- LI1 trial. Within the RAvVA 
outpatient trial, patients received either Azacitidine alone 
(75mg/m2 days 1-9) or a combination of Azacitidine (75mg/
m2 days 1-9) + Vorinostat (300mg BD days 3-9 PO) for six 
28-day cycles before assessment of response.
MATERIALS & METHODS
Patient selection
Inclusion criteria: Inpatient regimen included patients with 
newly diagnosed de novo or secondary AML (excluding 
Acute Promyelocytic Leukaemia; aPML) or high risk MDS 
(>10% blasts). Outpatient regimen included patients with de 
novo or secondary AML, including relapsed AML and able to 
undertake treatment on an outpatient basis. Inclusion criteria 
common to both groups include age >60, unfit for intensive 
chemotherapy and undergoing less intensive treatment within 
a clinical trial. All patients provided written informed consent. 
Exclusion criteria: aPML or blast transformation of CML, 
previous cytotoxic chemotherapy or allogenic haematopoietic 
stem cell transplant for AML,  concurrent active malignancy 
under treatment, pregnant or lactating, adults of reproductive 
potential not willing to use appropriate and effective 
contraception during the trial and specified time afterwards, 
serum creatinine of ≥175umol/L, AST ≥2.5 x ULN (Upper 
limit of normal) and/or ALP ≥2.5 x ULN, total bilirubin 
≥1.5 x ULN unless due to Gilbert’s syndrome, any active 
infection including fungal, bacterial and viral infections (HIV, 
Hepatitis), history of MI, unstable angina, cerebrovascular 
accident or TIA within 6 months. Further specific cardiac 
exclusion criteria were added for selected drugs used 
alongside low dose cytarabine in the inpatient regimen 
(Appendix 1).
Consecutive entrants to both trials between February 2013 
and January 2017 were included. Baseline characteristics 
were compared across both groups. Co-morbidities were 
graded using the Haematopoietic Cell Transplant Comorbidity 
Index (HCT-CI) indicating severity of co-morbidity and risk 
of mortality (0= low risk, 1-2= intermediate risk, >2=high 
risk) 8. Cytogenetic reports from Northern Ireland Regional 
Genetics Laboratory at Belfast City hospital were analysed 
using StarLims database and categorised into favourable, 
intermediate or poor cytogenetic risk.
Endpoints
Primary endpoint was overall survival (OS), measured from 
date of randomisation to trial as documented by Clinical Trials 
Nurse within patient notes, to date of death as documented on 
electronic care record (ECR). Alive patients were censored 
at date of analysis. 
Response
Response to therapy was evaluated following each cycle of 
treatment on the inpatient regimen and after six cycles of the 
outpatient regimen. Response was categorised as Complete 
remission (CR), complete remission with incomplete recovery 
of neutrophils or platelets (CRi), partial remission (PR) or 
none. Patients who died during treatment before evaluation 
of response were classified as ‘early deaths’9. Blood results 
of patients who experienced an ‘early death’ were analysed 
by a clinically trained researcher and further classified into 
‘Haematological Improvement’ (HI) or ‘no HI’ depending 
on trends of blood counts during and following treatment. 
Duration of response was calculated from time of confirmed 
remission to date of relapse on bone marrow biopsies (blast 
count >5%).
Toxicity criteria
Data for reported toxicities was sourced from patient notes, 
clinic letters and discharge letters. Patients within the 
outpatient trial had chemotherapy charts in which toxicities 
Appendix 1: 
Specific cardiac exclusion criteria for Ganetespib:
• Myocardial infarction within 12 months, uncontrolled angina 
within 6 months, current or history of congestive heart 
failure- New York Heart Association (NYHA) class 3 or 4 
unless an echocardiogram or multiple gated acquisition scan 
performed either within 1 month prior to study screening or 
during screening results in a left ventricular ejection fraction 
that is >45% or institutional lower limit of normal value.
• Diagnosed or suspected long QT syndrome. Any history of 
clinically significant ventricular arrhythmia.
• Prolonged QTc interval on pre-entry ECG
• Uncontrolled hypertension
• Obligate need for a pacemaker
• Complete left bundle branch block
• Uncontrolled atrial fibrillation
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were documented and graded by trained nursing staff. All 
toxicities were graded for severity using a scale from 1-4 as 
per National Cancer Institute Common Terminology Criteria 
for Adverse Events; NCI CTCAE v4 10.
Supportive care needs
Blood product use including platelets and packed red cells 
(units), number of hospital admissions, number of days spent 
in hospital, infections and antibiotic use were documented 
using patient notes, blood bank records and ECR. 
Statistical Analysis
Comparisons of baseline characteristics and supportive care 
requirements between RAvVA and the outpatient regimen 
were undertaken using the Mann-Whitney test. Kaplan-Meier 
curves were generated to depict overall survival in each 
group and overall survival was compared using the log rank 
test. Contingency analysis using the Chi-Squared test was 
undertaken to compare rates of response and the occurrence 
of severe toxicities in each group. For the purpose of these 
comparisons patients who died before undergoing a bone 
marrow biopsy were excluded from the analysis. All p-values 
reported are two-tailed, a p-value of < 0.05 was considered 
statistically significant. 
RESULTS
Description of study cohort
From an initial sample of 40 patients, a total of 37 patients 
were included, all of whom had a diagnosis of AML or 
high risk MDS between February 2013 and January 2017. 
Reasons for exclusion include one patient with age below 
60 years, and two patients who were initially enrolled on the 
inpatient regimen and subsequently entered the outpatient 
RAvVA trial following relapse. For these patients, analysis 
was limited to outcomes whilst on inpatient regimen only. 
Seventeen patients were part of the RAvVA outpatient-based 
trial, and 20 patients had or were undergoing treatment as 
an inpatient receiving low dose chemotherapy at the time of 
the study. Baseline characteristics are summarised in Table 
1. There were no significant differences between any of the 
variables analysed. Evaluation of cytogenetic risks in the 
inpatient regimen revealed 9 and 10 patients in the poor and 
intermediate categories, respectively, compared with 4 and 
13 patients in the outpatient group (p=0.71). One patient 
had incomplete cytogenetic analysis due to poor quality 
metaphases on cell culture.
Overall survival 
There was no significant difference in overall survival 
between inpatient and outpatient delivered regimens (Figure 
1), with a median no. of days of 201 vs. 124, respectively; 
p=0.3284. Overall percentage survival at 1 year was 19% and 
5% at 2 years, which is consistent with findings from similar 
studies 1,11,12.
Response
In those who underwent bone marrow examination rates 
of CR, CRi and PR (31%, 8% and 8% vs. 13%, 13% and 
0%, respectively) were not significantly different between 
inpatient and outpatient groups overall. There was a 
nominally greater rate of patients with no response to therapy 
in the outpatient group (73%, n=11) than the inpatient group 
(54%, n=7) but this failed to reach statistical significance (p= 
0.28). There was a trend to more early deaths in the inpatient 
group than the outpatient group (n= 7; 35% vs. n=2; 12% 
TAble 1: 
Baseline Characteristics
RAvVA Inpatient Regime
N 17 20
Gender (%) M= 71 M= 60
F= 29 F= 40
Median (SD)
Age (years) 72 (7.3) 72 (4.0)
Blast (%) 33 (31.2) 49.5 (30.1)
WCC on presentation (x109) 2.5 (14.0) 4.9 (14.3)
Platelets on presentation (x109) 34 (57.6) 29 (36.5)
Haemoglobin on presentation (g/L) 93 (11.4) 95 (20.8)
Severity of co-
morbidity: HCT CI 
score* (no of patients)
0 (low) 5 4
1-2 (intermediate) 5 7
>2 (high) 7 9
*HCT-CI (Haematopoietic Cell Transplant- Comorbidity 
Index) comprises 17 different categories of organ dysfunction 
and indicates severity of co-morbidities and risk of mortality.
RAvVA trial= Randomised Trial of 5-Azacitidine versus 
5-Azacitidine in combination with Vorinostat in patients 
with Acute Myeloid Leukaemia or High Risk Myelodysplastic 
Syndromes Ineligible for Intensive Chemotherapy
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Figure 1: Kaplan Meier curve showing overall survival for inpatient and outpatient 
based chemotherapy for AML in the elderly
Mantel Cox test p= 0.9591
Gehan Breslow Wilcoxin p= 0.3284
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Fig 1. Kaplan Meier curve showing overall survival for inpatient 
and outpatient (RAvVA trial) based chemotherapy for AML in 
elderly
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p=0.10). Further analysis of early deaths within both groups 
revealed a haematological improvement (HI) in one patient in 
both groups. It is possible that patients with early death and no 
HI may represent no response, therefore providing a potential 
explanation the lower rates of ‘no response’ in the inpatient 
group compared with the outpatient group. Of those who 
achieved CR or CRi in the outpatient group (n=4), seventy-
five percent relapsed with an average time to relapse of 252 
days (range 92-393). Sixty percent (n=3) of the patients who 
achieved CR or CRi in the Inpatient group relapsed with an 
average time to relapse of 236 days (range 170-330).
Toxicities
At baseline, 65.8% of all patients had a haemoglobin, white 
cell count or platelet count that would be classed as a grade 
3 or 4 toxicity as per NCI common toxicity criteria. Further 
analysis was limited to non-haematologic toxicities, of which 
the majority were mild- moderate at grade 1-2 (73% and 59% 
of all reported toxicities in outpatient and inpatient regimen, 
respectively). Interestingly, 83.3% of patients in the outpatient 
and 90% of the inpatient group experienced at least one grade 
3 or 4 toxicity which is defined as severe or life threatening. 
There were seven common grade 3 or 4 toxicities across both 
groups including sepsis, epistaxis, hypokalaemia, pulmonary 
oedema and fatigue (Table 2). There was no statistically 
significant difference between the two groups for any single 
grade 3/4 toxicity. Of note, over 50% of patients in both 
groups experienced life threatening sepsis.
Supportive Care Requirements
Unsurprisingly, patients treated on the outpatient regimen 
spent significantly less time in hospital with a calculated 
median number of days in hospital of 42 days compared 
with 80 days for inpatient group, including treatment days 
(p=0.0016). Both groups had a median of 2 hospitalisations, 
reflecting longer duration of in-hospital stay per admission 
on the inpatient regime. Despite this, packed red cell use was 
significantly higher in the outpatient group with a median of 
26.5 units, compared with 12.5 units for the inpatient group 
(p=0.038).  There was no difference between the outpatient 
and inpatient regimens for number of infections (median 3 
vs. 2; p=0.96), days on antibiotics; (41.5 vs 41; p=0.54); or 
units of platelets required (15 vs 14, p=0.93), respectively.
DISCUSSION
We aimed to identify and characterise differences in 
outpatient and inpatient based chemotherapy regimens 
for elderly patients with AML. To our knowledge, this is 
the first study to compare clinical setting for delivery of 
palliative chemotherapy in this group. The average cost of 
treating elderly patients with AML has been estimated at 
around $42,000 in a US study 12. Whilst treatment of AML 
has historically been associated with prolonged periods of 
hospitalisation, there has been much interest in shifting from 
inpatient to outpatient treatment to reduce medical resource 
utilisation and burden of hospitalisation 13. Interestingly, 
a number of studies have been carried out which support 
early discharge of patients following intensive induction/ 
salvage chemotherapy for AML and suggest delivery of 
supportive care as an outpatient to be safe without negatively 
impacting on survival 14-16. Similarly, the data presented here 
demonstrates no significant difference in the primary endpoint 
of overall survival or response to treatment between inpatient 
and outpatient delivery of chemotherapy (p= 0.3284). In 
keeping with the aim of reducing hospitalisation costs, there 
was a significant difference in the number of days spent 
in hospital with patients treated on the outpatient regimen 
spending on average less than half the time in hospital as 
patients on the inpatient regimen. Despite the observational 
nature of this study and baseline differences in patient 
characteristics, our work provides a rationale to explore the 
efficacy of this approach in interventional studies. 
As with all types of chemotherapy, monitoring toxicity and 
prompt access to medical care is imperative. Analysis of 
toxicity and supportive care needs in this study revealed a 
high percentage of patients in both groups experiencing at 
least one life threatening or severe toxicity, with over half of 
the patients in both groups experiencing sepsis. Comparison 
between groups showed significantly more mild to moderate 
toxicities and higher packed red cell use in the outpatient 
group. Possible explanations for this include more reporting 
of toxicities as a result of close monitoring by day unit staff 
on a chemotherapy chart in the outpatient regimen, and also 
the preparation of ‘standing orders’ of packed red cells for 
patients receiving outpatient chemotherapy in a day unit. 
Furthermore, inclusion of 6 patients with relapsed AML in 
the RAvVA trial, and no participants with relapsed AML in 
the inpatient regimen may have constituted a subgroup of 
patients with more advanced disease and a higher requirement 
for blood product support. Nevertheless, this suggests that 
with delivery of an outpatient-based chemotherapy regimen, 
patient education on early recognition of chemotherapy 
related complications and sepsis is essential, as well as 
adequate facilities to provide supportive medical treatment 
as required.
This study has several limitations, including a small sample 
size and absence of a sample size calculation, reducing 
the external validity. We relied on accurate documentation 
of toxicities, blood product use and antibiotic duration on 
TAble 2:
Grade 3/4 Toxicities
Grade 3/4 Toxicity IP regime RAvVA
Sepsis 13 9
Epistaxis 3 2
Hypokalaemia 2 3
Pulmonary oedema 2 1
Hyponatraemia 2 1
Fatigue 1 1
Hypotension 1 1
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discharge letters, patient notes and chemotherapy charts, 
many of which were not intended for research purposes. 
Different combinations of chemotherapy were a baseline 
confounding variable. 
CONCLUSION
Survival of elderly patients with AML remains unfavourable 
even with advances in treatments over recent decades. Despite 
less intensive treatments with palliative chemotherapy, the 
burden of toxicities and hospitalisations for patients in this 
age group is still noteworthy. We postulate that there may 
be a role for outpatient-based chemotherapy in reducing 
hospitalisations and enhancing quality of life for elderly 
patients with AML without a decline in overall survival or 
response rates. A larger scale randomised controlled trial to 
compare inpatient and outpatient delivery of chemotherapy 
would be a suitable way to clarify this further.
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